NRx Pharmaceuticals notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.
NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters' Option
NRx Pharmaceuticals Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026
NRx Pharmaceuticals Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
NRx Pharmaceuticals, Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update
NRx Pharmaceuticals Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and Suicidality
NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program
NRx Pharmaceuticals Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality
NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications
NRx Pharmaceuticals Announces Appointment of Glenn Tyson as the Company's first Chief Commercial Officer
NRx Pharmaceuticals Announces FDA Labeling Alignment for NRx's Preservative-Free Ketamine Application
Steadright Removes Titanbeach One Technical Report And Retains Qualified Geologist For New Technical Report
The Metal You've Never Heard Of Is Becoming a National-Security Priority -- and America Barely Mines It
